MGTX$9.321.79%-0.17
Meiragtx Holdings Plc (MGTX)
Date: 2026-11-02 16:00O: 9.49H: 9.52L: 9.20C: 9.32Vol: 580.1k
Meiragtx Holdings Plc stock is traded at $9.32, with a volume of 580,105. It is down -1.79% in the last 24 hours and down -13.62% over the past month. MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Previous Close:
$9.49
Open:
$9.49
24h Volume:
580,105
Relative Volume:
0.97
Market Cap:
$895.12M
Revenue:
$79.76M
Net Income/Loss:
-$120.53M
P/E Ratio:
-
EPS:
-$1.49
Net Cash Flow:
$3.75M
1W Performance:
-0.85%
1M Performance:
-13.62%
6M Performance:
-0.96%
1Y Performance:
+6.76%
1-Day Range:
$0.00$0.00
1-Week Range:
$9.11$9.92
52-Week Range:
$6.62$15.35
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings PlcSector
HealthcareIndustry
BiotechnologyPhone
646-860-7985Address
655 THIRD AVENUE, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Meiragtx Holdings Plc Stock (MGTX) Insider Trading
- Giroux RichardOct 20 '26CFO & COO
- Transaction
- Sale
- Cost
- $9.95
- #Shares
- 56,000
- Value ($)
- 557,200
- #Shares Total
- 852,530
- Richard GirouxOct 20 '26Officer
- Transaction
- Proposed Sale
- Cost
- $9.95
- #Shares
- 56,000
- Value ($)
- 557,200
- #Shares Total
- 0
- Naylor StuartOct 06 '26Officer
- Transaction
- Proposed Sale
- Cost
- $10.64
- #Shares
- 27,659
- Value ($)
- 294,321
- #Shares Total
- 0
- Naylor StuartOct 06 '26CHIEF SCI OFCR, OPHTHALMOLOGY
- Transaction
- Sale
- Cost
- $10.64
- #Shares
- 27,659
- Value ($)
- 294,292
- #Shares Total
- 613,187
- Alexandria ForbesAug 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $13.86
- #Shares
- 62,000
- Value ($)
- 859,320
- #Shares Total
- 0
- Forbes AlexandriaAug 18 '26PRESIDENT & CEO
- Transaction
- Sale
- Cost
- $13.86
- #Shares
- 62,000
- Value ($)
- 859,320
- #Shares Total
- 1,325,695
- Giroux RichardJul 21 '26CFO & COO
- Transaction
- Sale
- Cost
- $12.51
- #Shares
- 56,000
- Value ($)
- 700,560
- #Shares Total
- 908,530
- Richard GirouxJul 21 '26Officer
- Transaction
- Proposed Sale
- Cost
- $12.51
- #Shares
- 56,000
- Value ($)
- 700,560
- #Shares Total
- 0
- Naylor StuartJul 07 '26CHIEF SCI OFCR, OPHTHALMOLOGY
- Transaction
- Sale
- Cost
- $14.80
- #Shares
- 27,659
- Value ($)
- 409,470
- #Shares Total
- 640,846
- Naylor StuartJul 07 '26Officer
- Transaction
- Proposed Sale
- Cost
- $13.33
- #Shares
- 27,659
- Value ($)
- 368,694
- #Shares Total
- 0
